PINX1 and ovarian carcinoma: To further assess the impact of PINX1 deficiency on the efficacy of PARP inhibitors in vivo, we established a xenograft model in NSG mice using ovarian carcinoma-derived cell line OC316 with or without PINX1 knock-down (Fig. 2G).